> 
Roche ($RHHBY) officially opened its 41-story site in Basel, Switzerland. Management is painting the decision to build a skyscraper--which at 178 meters tall dwarfs any other building in Switzerland and can be seen from France and Germany--as a practical response to the lack of space in Basel. Some outsiders have a different take. "This new building can be seen as a defiant reaction to the arrival of others moving into a space Roche has dominated for the last 15 years," Zuercher Kantonalbank analyst Michael Nawrath told Reuters. Reuters
> Replimune raised $30 million (€27 million) from Atlas Venture, Forbion Capital Partners and Omega Funds in a Series A round. The round gives the recently founded company money to advance its R&D into oncolytic immunotherapies, a class of products it sees meshing well with checkpoint blockades and other immune-modulatory therapeutic approaches. BioVex founder Robert Coffin is leading the company, which is based out of Oxford, U.K., but is also building up its operations in Cambridge, MA. FierceBiotech
> MorphoSys (ETR:MOR) posted updated data from the ongoing Phase I/IIa trial of MOR202, the CD38-targeting multiple myeloma drug that Celgene ($CELG) walked away from earlier this year. The data support the safety and efficacy picture MorphoSys started to put together at ASCO. A handful of the 50 heavily treated multiple myeloma patients have now responded to the treatment and the study is yet to hit its maximum tolerated dose. The updated dataset includes patients who received 16 mg/kg of MOR202 in combination with dexamethasone. Release
> ReNeuron (AIM:RENE) outlined how it will deploy its recently inflated bank balance. The British stem cell therapy specialist is readying a suite of clinical development programs using the £68.4 million ($104.4 million) it raised from Neil Woodford and others this year. Pivotal Phase II/III trials of stem cell treatments for disability caused by ischaemic stroke and retinitis pigmentosa are both pencilled into the calendar. Statement
> Galapagos ($GLPG) presented early data on GLPG1690, an autotaxin inhibitor it sees as a possible treatment for idiopathic pulmonary fibrosis. The preclinical and Phase I data published this week only give a sketch of the therapeutic properties of GLPG1690 but Galapagos has seen enough to start work on further development. A filing for an exploratory Phase II study in idiopathic pulmonary fibrosis is the next step. Release
> UniQure ($QURE) disclosed top-line results from a Phase I/II trial of its gene therapy AMT-110 in people with Sanfilippo B syndrome. Having given data from the four-person trial the once over, uniQure is now preparing to advance the program into a pivotal study and take over responsibility for its progress from the consortium that has advanced it to date. FierceBiotech